Literature DB >> 6892691

A simplified assay for dihydroxylated vitamin D metabolites in human serum: application to hyper- and hypovitaminosis D.

R S Mason, D Lissner, H S Grunstein, S Posen.   

Abstract

We describe a simplified assay for 24,25-and 1.25-dihydroxyvitamin D in human serum. It involves two preparative steps, and normal chick intestine is used in preparing cytosol-binding protein. Our results for 24,25-dihydroxyvitamin D include a reference interval of 2.9--16 nmol/L (1.2--6.7 microgram/L), a mean of 6.7 nmol/L (2.8 microgram/L), an intra-assay CV of 11%, and an interassay CV of 22%. For 1,25-dihydroxyvitamin D, these data were 29--168 pmol/L (12--70 ng/L), 86 pmol/L (36 ng/L), 12%, and 22%, respectively. In hypoparathyroid patients with vitamin D intoxication, mean concentrations of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D in serum were significantly above normal; the 1,25-dihydroxyvitamin D concentrations were significantly below normal. Patients with malabsorption and/or post-gastrectomy states had significantly subnormal values for both 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D in serum, and there was a significantly negative correlation between each of these biochemical values and the severity of osteomalacia. We also discuss cost effectiveness of assaying vitamin D metabolites in human serum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6892691

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

Review 1.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

2.  Simultaneous measurement of 1.25-dihydroxy-vitamin D, 24.25-dihydroxy-vitamin D and 25-hydroxy-vitamin D from a single two milliliters serum specimen. Preliminary clinical application.

Authors:  D Tartarotti; S Adami; G Galvanini; R Dorizzi; G Piemonte; V Lo Cascio
Journal:  J Endocrinol Invest       Date:  1984-12       Impact factor: 4.256

3.  Skeletal changes in preterm infants.

Authors:  W W Koo; J M Gupta; V V Nayanar; M Wilkinson; S Posen
Journal:  Arch Dis Child       Date:  1982-06       Impact factor: 3.791

4.  1,25-Dihydroxyvitamin D3 down-regulation of HLA-DR on human peripheral blood monocytes.

Authors:  N Tokuda; N Mizuki; M Kasahara; R B Levy
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

5.  Effects of weight loss on serum 1,25-(OH)2-vitamin D concentrations in adults: a preliminary report.

Authors:  J Lemann; R W Gray; W J Maierhofer; N D Adams
Journal:  Calcif Tissue Int       Date:  1984-03       Impact factor: 4.333

6.  Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes.

Authors:  A Clavreul; C L D'hellencourt; C Montero-Menei; G Potron; D Couez
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

7.  Effect of aluminum on normal and uremic rats: tissue distribution, vitamin D metabolites, and quantitative bone histology.

Authors:  Y L Chan; A C Alfrey; S Posen; D Lissner; E Hills; C R Dunstan; R A Evans
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

8.  The effect of metabolic acidosis on vitamin D metabolites and bone histology in uremic rats.

Authors:  Y L Chan; E Savdie; R S Mason; S Posen
Journal:  Calcif Tissue Int       Date:  1985-03       Impact factor: 4.333

9.  Adjuvant therapy with high dose vitamin D following primary treatment of melanoma at high risk of recurrence: a placebo controlled randomised phase II trial (ANZMTG 02.09 Mel-D).

Authors:  Robyn P M Saw; Bruce K Armstrong; Rebecca S Mason; Rachael L Morton; Kerwin F Shannon; Andrew J Spillane; Jonathan R Stretch; John F Thompson
Journal:  BMC Cancer       Date:  2014-10-24       Impact factor: 4.430

Review 10.  Vitamin D: deficiency, sufficiency and toxicity.

Authors:  Fahad Alshahrani; Naji Aljohani
Journal:  Nutrients       Date:  2013-09-13       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.